In this study, we evaluated the therapeutic potential of WPP and CPP in the treatment of hyperuricaemia by measuring XO activity inhibition, the levels of UA, Cr and UN in serum and urine and the expression of ICAM-1, IL-1β and IL-6, and by observing kidney histological damage. Here, ICAM1 is linked to hyperuricemia.